{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:36:11Z","timestamp":1776324971216,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ygyno.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:31:43Z","timestamp":1753277503000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage"],"prefix":"10.1016","volume":"200","author":[{"given":"Kevin J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Chokshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanvi","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Ramirez-Alcantara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elba A.","family":"Turbat-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney P.","family":"Rocconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Scalici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.07.016_bb0005","author":"Henley"},{"issue":"13","key":"10.1016\/j.ygyno.2025.07.016_bb0010","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of Cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2025.07.016_bb0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1055\/a-1545-4279","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"H\u00f6hn","year":"2021","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"6","key":"10.1016\/j.ygyno.2025.07.016_bb0020","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3390\/cancers13061478","article-title":"The TCGA molecular classification of endometrial Cancer and its possible impact on adjuvant treatment decisions","volume":"13","author":"Alexa","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.016_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.016_bb0030","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","article-title":"Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity","volume":"160","author":"Matsuzaki","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.07.016_bb0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine Carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2025.07.016_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103369","article-title":"Uterine carcinosarcoma: An overview","volume":"163","author":"Pezzicoli","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.016_bb0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/GRF.0b013e318218c755","article-title":"Uterine papillary serous carcinoma","volume":"54","author":"Moore","year":"2011","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2023.152173","article-title":"Distinct histological and clinical features associated with pure uterine serous carcinoma: a single institution experience","volume":"66","author":"Zhi","year":"2023","journal-title":"Ann. Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GCO.0b013e328334d8a3","article-title":"Uterine papillary serous carcinoma: epidemiology, pathogenesis and management","volume":"22","author":"Fader","year":"2010","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"6230","key":"10.1016\/j.ygyno.2025.07.016_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"6286","key":"10.1016\/j.ygyno.2025.07.016_bb0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \u201ccancer immunogram.\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"issue":"36","key":"10.1016\/j.ygyno.2025.07.016_bb0070","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of Pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical Cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.016_bb0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1\u2013positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0080","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2017.07.026","article-title":"Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine","volume":"84","author":"Nebot-Bral","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0090","article-title":"Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant","author":"Yang","year":"2020","journal-title":"Front Immunol. 2020 Oct 6;11:577869. doi: 10.3389\/fimmu.2020.577869. PMID: 33123161; PMCID: PMC7572849Front Immunol [Internet]"},{"issue":"3","key":"10.1016\/j.ygyno.2025.07.016_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance Durvalumab with or without Olaparib as first-line treatment for advanced endometrial Cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.07.016_bb0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2024.11.006","article-title":"Repair assisted damage detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer","volume":"192","author":"Sonavane","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.crbiot.2019.11.001","article-title":"DNA damage measurements within tissue samples with repair assisted damage detection (RADD)","volume":"1","author":"Lee","year":"2019","journal-title":"Curr Res Biotechnol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/biology10050385","article-title":"Associations between DNA damage and PD-L1 expression in ovarian Cancer, a potential biomarker for clinical response","volume":"10","author":"Mann","year":"2021","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.ygyno.2025.07.016_bb0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann. Stat."},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0125","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/0008-5472.CAN-20-2121","article-title":"Differential regulation of Cancer progression by CDK4\/6 plays a central role in DNA replication and repair pathways","volume":"81","author":"Dai","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2025.07.016_bb0135","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.3390\/ijms23169313","article-title":"The chromatin remodeler HELLS: a new regulator in DNA repair, genome maintenance, and Cancer","volume":"23","author":"Peixoto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ygyno.2025.07.016_bb0140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/ng1627","article-title":"The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair","volume":"37","author":"Bridge","year":"2005","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.ygyno.2025.07.016_bb0145","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.molcel.2024.02.010","article-title":"CDK-independent role of D-type cyclins in regulating DNA mismatch repair","volume":"84","author":"Rona","year":"2024","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","article-title":"Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair","volume":"149","author":"D\u2019Angiolella","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-015-3657-z","article-title":"Survivin contributes to DNA repair by homologous recombination in breast cancer cells","volume":"155","author":"V\u00e9quaud","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.radonc.2011.06.037","article-title":"Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma","volume":"101","author":"Reichert","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0165","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","article-title":"Hdac3 is essential for the maintenance of chromatin structure and genome stability","volume":"18","author":"Bhaskara","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129760","article-title":"Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment","volume":"1865","author":"Balboni","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/cr.2007.115","article-title":"Mechanisms and functions of DNA mismatch repair","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0180","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.gene.2016.06.031","article-title":"POLD1: central mediator of DNA replication and repair, and implication in cancer and other pathologies","volume":"590","author":"Nicolas","year":"2016","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.ygyno.2025.07.016_bb0185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","article-title":"Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells","volume":"48","author":"Li","year":"2018","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.ygyno.2025.07.016_bb0190","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1111\/febs.15637","article-title":"The multifaceted role of TRAIL signaling in cancer and immunity","volume":"288","author":"Cardoso Alves","year":"2021","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0195","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1080\/21655979.2021.1985858","article-title":"Interferon alpha-inducible protein 27 (IFI27) is a prognostic marker for pancreatic cancer based on comprehensive bioinformatics analysis","volume":"12","author":"Huang","year":"2021","journal-title":"Bioengineered"},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109309","article-title":"Integrin \u03b1v\u03b28 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy","volume":"36","author":"Dodagatta-Marri","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0205","article-title":"IL-6: the link between inflammation, immunity and breast Cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.07.016_bb0210","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.immuni.2022.10.020","article-title":"The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity","volume":"55","author":"Lukhele","year":"2022","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.ygyno.2025.07.016_bb0215","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.3390\/ijms21217955","article-title":"CCL18 in the progression of Cancer","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155961","article-title":"IL-33 biology in cancer: an update and future perspectives","volume":"157","author":"Yeoh","year":"2022","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.016_bb0225","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/cells10020355","article-title":"NF-\u03baB in Cancer immunity: friend or foe?","volume":"10","author":"Lalle","year":"2021","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.ygyno.2025.07.016_bb0230","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0235","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12967-018-1611-7","article-title":"Unleashing endogenous TNF-alpha as a cancer immunotherapeutic","volume":"16","author":"Josephs","year":"2018","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2025.07.016_bb0240","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0245","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas: morphologic and Immunohistochemical features, diagnostic challenges and recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.07.016_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijgo.13937","article-title":"Prognostic value of the TCGA molecular classification in uterine carcinosarcoma","volume":"158","author":"Travaglino","year":"2022","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"8","key":"10.1016\/j.ygyno.2025.07.016_bb0255","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/pathogens13080619","article-title":"Newcastle disease virus induces profound lymphoid depletion with different patterns of necroptosis, necrosis, and oxidative DNA damage in Bursa, spleen, and other lymphoid tissues","volume":"13","author":"Rabiei","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.ygyno.2025.07.016_bb0260","doi-asserted-by":"crossref","first-page":"4719194","DOI":"10.1155\/2017\/4719194","article-title":"Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy","volume":"2017","author":"Viale","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2025.07.016_bb0265","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3389\/fimmu.2019.01654","article-title":"Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on Cancer","volume":"10","author":"Opzoomer","year":"2019","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.ygyno.2025.07.016_bb0270","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2025.07.016_bb0275","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2025.07.016_bb0280","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for advanced endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:43:31Z","timestamp":1758915811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825009266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"alternative-id":["S0090825825009266"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}